Rheumatoid Arthritis
  Richard Conway RichardPAConway
            3 years 5 months ago 
          
         
          Karpouzas et al. ORAL Surveillance analysis. MACE, VTE, infections higher in those with acute and cumulative disease activity as measured by CDAI. @RheumNow #EULAR2022 POS0519 https://t.co/CtlISf2rxr
        
        
  Richard Conway RichardPAConway
            3 years 5 months ago 
          
         
          Rojas-Gimenez et al After adjusting for age, smoking, ACPA. Male sex (OR 4.2) and longer time of having RA (OR 1.08) associated with ILD @RheumNow #EULAR2022 POS0619 https://t.co/kzG76Qwe52
        
        
  Eric Dein ericdeinmd
            3 years 5 months ago 
          
         
          #EULAR2022 OP0134: Active RA increases risk of dementia
Olmsted County, MINN studying RA risk factors for dementia:
⭐️886 pts incident RA, mean age 65. 103 develop dementia
Risk factors: Age, rheum nodules, large jt swelling, depression/anxiety, HTN, CVD events
@Rheumnow https://t.co/bUFkzBovAy
        
        
  Aurelie Najm AurelieRheumo
            3 years 5 months ago 
          
         
          All the domains of sexual sphere are deteriorated in RA and PsA.
This aspect is often overlooked and can have a significant impact on pts QoL. It may be time to assess this aspect more specifically using CSFQ-14 and propose dedicated interventions. #OP0139 @RheumNow #EULAR2022 https://t.co/l0zyBIZ1LI
        
        
  Eric Dein ericdeinmd
            3 years 5 months ago 
          
         
          #EULAR2022 OP0139
Has your pt asked about sexual fxn?
Sexual dysfxn (SD) (CSFQ-14 questionnaire) and joint disease
188 AI pts, 89 controls
Nearly 50% of RA pts had SD, 30% in PsA. Only 6% in control group!
High depression in group, but not found as rf
@RheumNow https://t.co/WvBw3cnFKC
        
        
  David Liew drdavidliew
            3 years 5 months ago 
          
         
          Patient with 12 weeks inflamm-sounding arthralgias and functional impairment, high titre RF/CCP, osteitis on MRI, no clinical synovitis on exam.
Do you suggest to patient to treat with methotrexate?
#EULAR2022 @RheumNow
        
        
  Aurelie Najm AurelieRheumo
            3 years 5 months ago 
          
         
          🚨 Study on MTX and male fertility 
Analysis of semen parameters in
🙋🏼♂️HC
🙋🏼♂️RA, PsA and PsO MTX naive
🙋🏼♂️Post MTX
Reassuring data as NO significant effect of MTX was observed on several semen parameters.
#EULAR2022 @RheumNow
OP0131 https://t.co/Fq32lzAMAx
        
        
  Aurelie Najm AurelieRheumo
            3 years 5 months ago 
          
         
          Dementia in RA associated w/
⚡️Large joint swelling HR 2
⚡️Any CVD HR 2.25
⚡️Anxiety HR 1.86
⚡️Depression HR 2.63
at any time during disease course in retrospective cohort 800+ pts
#EULAR2022 @RheumNow OP0134 @MyasoedovaElena https://t.co/MLweRMEZXE
        
        
  Eric Dein ericdeinmd
            3 years 5 months ago 
          
         
          #EULAR2022 OP0135:
German RABBIT 🐇 Registry:
⭐️ Observational, 46% Tofa, 54% Bari
No increased rate of CVD in JAK vs TNF inhibitor
🚨Unlike the ORAL Surveillance
@RheumNow https://t.co/O4IXg22Ybc
        
        
  Eric Dein ericdeinmd
            3 years 5 months ago 
          
         
          #EULAR2022 OP0136:
PROTECT-RA Cohort - 150 pts established RA
Cholesterol loading capacity (CLC) on macrophages
⭐️High CLC correlates with CV events
⭐️bDMARD use affects CLC
@RheumNow https://t.co/9ngaH9yUI7
        
        
  Aurelie Najm AurelieRheumo
            3 years 5 months ago 
          
         
          RABBIT registry and MACE in RA
No difference between
*JAKi (Tofa and Bari) and *TNFi in both unselected and high CV risks patients.
🧨 different than ORAL surveillance 
but Observational and overall Low incidence (28 events).
#EULAR2022 @RheumNow OP0135 https://t.co/o8rngHrwQF
        
        
  Dr. Antoni Chan synovialjoints
            3 years 5 months ago 
          
         
          The CONSUL study @ProftDr showed there was no significant difference in Celecoxib(CEL)+Golimumab (GOL) vs GOL alone. The mSASSS change was 1.1 vs 1.7, p=0.79 between the 2 groups. The combination may be clinically relevant in high-risk progressors #EULAR2022 @RheumNow OP0018 https://t.co/AUOL7IDx9L
        
        
        
      It’s good to be back into full, big meeting mode.
Highlights included a EULAR Recommendation Session, where updated guidelines were presented for the management of a) ANCA-associated Vasculitis, b) ASAS/EULAR recommendations for axSpA and c) RA. Here are a few of my favorites from Day 1.
    
  
  Aurelie Najm AurelieRheumo
            3 years 5 months ago 
          
         
          MIRACLE study: High or Low dose MTX w/ ADA in eRA?
✨ LOWd (6-8mg/w) 38.4% non-inferior to HIGHd (>10mg/w) 44.8% 
✨But safety profile looks better 9.1% vs 22.1% 👀
Are you already looking for minimal dose of MTX in patients treated w/ biologics?
#OP0062 @Rheumnow #EULAR2022 https://t.co/dq0EIKSnOe
        
        
  
Poster Hall